| Literature DB >> 35110307 |
Patsy Yates1, Rob Carter2, Robyn Cockerell3, Donna Cowan4, Cyril Dixon4,5, Anita Lal2, Robert U Newton6,7, Nicolas Hart3,6, Daniel A Galvão6, Brenton Baguley7,8, Nicholas Denniston9, Tina Skinner7, Jeremy Couper10, Jon Emery11, Mark Frydenberg12, Wei-Hong Liu3.
Abstract
OBJECTIVE: To evaluate the implementation of a multicomponent survivorship programme for men with prostate cancer and their carers.Entities:
Keywords: oncology; prostate disease; urological tumours; urology
Mesh:
Year: 2022 PMID: 35110307 PMCID: PMC8811561 DOI: 10.1136/bmjopen-2021-049802
Source DB: PubMed Journal: BMJ Open ISSN: 2044-6055 Impact factor: 2.692
Figure 1TrueNTH care model.
Definition of TrueNTH care pathway and data collection points
| Allocated subgroups | Definition | Preintervention | After enrolment in the intervention | |||
| T0 | T1 | T2 | T3 | T4 | ||
| Active surveillance | Men with localised prostate cancer who were undergoing active surveillance | At enrolment | 3 months | 5 months | 8 months | 12 months |
| Radiation therapy | Men with localised prostate cancer who were undergoing radiation therapy | At enrolment | / | 5 months | 8 months | 12 months |
| Surgery | Men with localised prostate cancer who were undergoing surgery or completed surgery no more than 3 months | At enrolment | 3 months | 6 months | 9 months | 12 months |
| Treatment completed | Men with localised prostate cancer who had completed primary treatment | At enrolment | 3 months | 6 months | 9 months | 12 months |
| Advanced prostate cancer | Men with advanced prostate cancer who had metastatic disease or biochemical recurrence progressing before or after salvage treatment, or who were ineligible for salvage treatment | At enrolment | 3 months | 6 months | / | 12 months |
/ indicates no data collection occurred at the time.
Figure 2Flow diagram of recruitment and participation.
Demographic and clinical characteristics of men (n=142) at enrolment
| Clinical characteristics | All men (n=142) | TrueNTH care pathway | ||||
| Active surveillance | Radiation (n=6) | Surgery (n=28) | Treatment completed | Advanced disease | ||
| Age in years, mean (SD) | 65.8 (8.6) | 61.9 (10.2) | 69.8 (4.0) | 61.9 (7.8) | 66.9 (8.8) | 68.3 (7.2) |
| Age groups, n (%) | ||||||
| <41 | 1 (1) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| 41–50 | 4 (3) | 0 (0) | 0 (0) | 2 (7) | 2 (3) | 0 (0) |
| 51–60 | 29 (20) | 6 (38) | 0 (0) | 9 (32) | 8 (14) | 6 (18) |
| 61–70 | 65 (46) | 6 (38) | 3 (50) | 12 (43) | 30 (52) | 14 (41) |
| 71–80 | 34 (24) | 2 (12) | 3 (50) | 5 (18) | 12 (21) | 12 (35) |
| 80+ | 9 (6) | 1 (6) | 0 (0) | 0 (0) | 6 (10) | 2 (6) |
| Age at diagnosis, mean (SD) | 62.6 (8.8) | 59.2 (10.2) | 69.5 (3.9) | 61.1 (7.4) | 62.8 (9.6) | 63.8 (7.8) |
| Time since diagnosis (months), median (range) | 19 (1–196) | 22 (1–123) | 4 (3–5) | 4 (1–88) | 32 (7–196) | 37 (1–175) |
| Time since diagnosis (months), n (%) | ||||||
| <3 | 14 (10) | 4 (25) | 0 (0) | 9 (32) | 0 (0) | 1 (3) |
| 3–6 | 27 (19) | 3 (19) | 6 (100) | 14 (50) | 0 (0) | 4 (12) |
| 7–12 | 16 (11) | 1 (6) | 0 (0) | 1 (4) | 10 (17) | 4 (12) |
| 13–24 | 21 (15) | 0 (0) | 0 (0) | 2 (7) | 14 (24) | 5 (15) |
| 25–36 | 13 (9) | 2 (12) | 0 (0) | 0 (0) | 8 (14) | 3 (9) |
| >36 | 51 (36) | 6 (38) | 0 (0) | 2 (7) | 26 (45) | 17 (50) |
| Stage of prostate cancer at enrolment, n (%) | ||||||
| Localised | 83 (59) | 16 (100) | 4 (67) | 21 (75) | 42 (72) | 0 (0) |
| Locally advanced | 36 (25) | 0 (0) | 2 (33) | 7 (25) | 16 (28) | 11* (32) |
| Distant metastases | 23 (16) | 0 (0) | 0 (0) | 0 (0.0) | 0 (0.0) | 23 (68) |
| Treatment received, n (%) | ||||||
| Active surveillance | 24 (17) | 16 (100) | 0 (0) | 3 (11) | 5 (9) | 0 (0) |
| Surgery | 85 (60) | N/A | 0 (0) | 28 (100) | 40 (69) | 17 (50) |
| Hormone therapy | 56 (39) | N/A | 5 (83) | 1 (4) | 19 (33) | 31 (91) |
| Radiation therapy | 47 (33) | N/A | 6 (100) | 0 (0) | 24 (41) | 17 (50) |
| Chemotherapy | 12 (9) | N/A | 0 (0) | 0 (0) | 0 (0) | 12 (35) |
*With biochemical recurrence.
N/A, not applicable; SD, Standard deviation.
Utilisation of the TrueNTH services over 12 months (total number of men=142)
| TrueNTH services | No of participants (%) | No of episodes | No of episodes per participant | Length of episodes per participant median (range) (in minutes) | |||
| Total | Phone | Teleconference | |||||
| Care coordination (initial consultation) | 142 (100) | 142 | 142 | 0 | 0 | 1 (1–1) | 60 (10–130) |
| Care coordination (follow-up) | 137 (97) | 750 | 600 | 7 | 143 | 5 (0–17) | 145 (10–630) |
| Nutrition support | 80 (56) | 203 | 178 | 8 | 17 | 2 (1–8) | 70 (5–275) |
| Exercise prescription | 89 (63) | 356 | 280 | 1 | 75 | 2 (1–17) | 35 (2–184) |
| Psychosocial support | 15 (11) | 77 | 75 | 1 | 1 | 3 (1–21) | 95 (15–505) |
| Sexual health | 10 (7) | 28 | 22 | 0 | 6 | 2 (1–6) | 145 (60–270) |
| Continence support | 9 (6) | 22 | 22 | 0 | 0 | 2 (1–5) | 45 (7–70) |
Prostate cancer-specific quality of life of men (n=142) by care pathway
| Group | Time point | Domain | |||||||||
| Urinary incontinence | Urinary obstructive | Bowel | Sexual | Hormonal | |||||||
| n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | n | Mean (SD) | ||
| All men (n=142) | T0 | 124 | 69.9 (32.3) | 118 | 82.8 (20.6) | 114 | 90.5 (14.4) | 123 | 28.0 (28.2) | 123 | 76.8 (20.5) |
| T2 | 99 | 73.4 (27.0) | 94 | 84.5 (17.6) | 95 | 90.1 (15.7) | 97 | 25.0 (25.5) | 96 | 76.9 (21.5) | |
| T4 | 92 | 74.8 (27.0) | 88 | 85.0 (18.9) | 85 | 92.2 (15.4) | 92 | 25.1 (26.3) | 87 | 78.2 (22.0) | |
| Change T2–T0 | 94 | 4.8 | 87 | 86 | 1.5 | 92 | −2.0 | 91 | 2.1 | ||
| Change T4–T0 | 87 | 4.4 | 81 | 2.4 | 76 | 1.3 | 88 | −1.1 | 82 | 3.7 | |
| Change over time | 78 | P=0.18 | 71 | P=0.10 | 68 | P=0.68 | 78 | P=0.42 | 73 | P=0.12 | |
| Active surveillance | T0 | 16 | 87.5 (16.5) | 15 | 91.3 (11.0) | 16 | 96.1 (9.6) | 16 | 66.0 (24.4) | 16 | 90.9 (13.6) |
| T2 | 13 | 89.6 (15.2) | 13 | 93.3 (10.0) | 13 | 95.8 (11.8) | 13 | 57.5 (35.3) | 13 | 91.2 (14.3) | |
| T4 | 13 | 88.2 (17.8) | 13 | 91.8 (10.0) | 12 | 97.9 (4.9) | 13 | 54.6 (35.5) | 12 | 91.7 (13.4) | |
| Change T2–T0 | 13 | 3.0 | 12 | 4.2 | 13 | 0.6 | 13 | −8.2 | 13 | 1.9 | |
| Change T4–T0 | 13 | 3.0 | 12 | 2.1 | 12 | 2.8 | 13 | −7.7 | 12 | 2.9 | |
| Change over time | 11 | P=0.74 | 10 | P=0.25 | 10 | P=0.49 | 11 | P=0.32 | 10 | P=0.66 | |
| Radiation (n=6) | T0 | 4 | 95.2 (9.7) | 4 | 82.8 (10.7) | 4 | 99.0 (2.1) | 4 | 33.0 (31.2) | 3 | 75.0 (17.3) |
| T2 | 3 | 92.4 (7.3) | 3 | 77.1 (15.7) | 3 | 86.1 (20.6) | 3 | 12.2 (21.1) | 3 | 75.8 (11.8) | |
| T4 | 2 | 100.0 (0.0) | 2 | 90.6 (4.4) | 2 | 93.8 (2.9) | 2 | 18.3 (2.4) | 3 | 76.7 (25.9) | |
| Change T2–T0 | 3 | − | 3 | − | 3 | − | 3 | − | 2 | ||
| Change T4–T0 | 2 | 0.0 | 2 | 0.0 | 2 | − | 2 | −3.9 | 1 | ||
| Change over time | 2 | P=0.50 | 2 | P=0.59 | 2 | P=0.49 | 2 | P=0.54 | 1 | / | |
| Surgery (n=28) | T0 | 24 | 59.3 (38.7) | 24 | 83.6 (16.8) | 24 | 92.9 (10.2) | 23 | 33.8 (31.0) | 24 | 84.7 (16.3) |
| T2 | 18 | 66.0 (29.7) | 17 | 87.1 (15.5) | 17 | 94.4 (7.8) | 17 | 24.5 (21.6) | 17 | 81.3 (16.0) | |
| T4 | 16 | 75.9 (24.7) | 16 | 92.4 (8.3) | 16 | 95.8 (7.0) | 16 | 24.5 (24.4) | 16 | 84.7 (18.1) | |
| Change T2–T0 | 17 | 16 | 16 | 3.1 | 15 | −9.2 | 16 | 1.0 | |||
| Change T4–T0 | 15 | 15 | 15 | 3.1 | 15 | − | 15 | 2.7 | |||
| Change over time | 14 | P=0.32 | 13 | P=0.08 | 13 | P=0.34 | 13 | P=0.13 | 13 | P=0.41 | |
| Treatment completed | T0 | 51 | 64.0 (34.3) | 48 | 85.0 (18.6) | 46 | 89.6 (17.0) | 52 | 19.7 (22.2) | 51 | 77.7 (17.8) |
| T2 | 42 | 71.3 (27.8) | 39 | 87.3 (15.3) | 39 | 91.6 (13.2) | 42 | 23.1 (21.3) | 40 | 80.6 (18.9) | |
| T4 | 37 | 73.5 (27.6) | 34 | 86.9 (16.6) | 33 | 91.5 (15.8) | 37 | 23.9 (24.1) | 34 | 82.2 (16.6) | |
| Change T2–T0 | 40 | 37 | 35 | 3.8 | 41 | 5.5 | 39 | ||||
| Change T4–T0 | 36 | 33 | 0.8 | 31 | 1.6 | 37 | 8.3 | 34 | |||
| Change over time | 32 | P=0.11 | 29 | P=0.24 | 28 | P=0.73 | 33 | P=0.09 | 31 |
| |
| Advanced disease | T0 | 29 | 75.9 (25.1) | 27 | 73.6 (28.7) | 24 | 84.8 (14.7) | 28 | 16.4 (16.3) | 29 | 61.1 (22.5) |
| T2 | 23 | 71.2 (27.0) | 22 | 73.3 (21.9) | 23 | 81.7 (21.9) | 22 | 11.7 (10.2) | 23 | 59.3 (24.0) | |
| T4 | 24 | 67.0 (30.0) | 23 | 72.6 (25.5) | 20 | 87.4 (21.5) | 22 | 12.1 (9.7) | 23 | 60.8 (25.7) | |
| Change T2–T0 | 21 | 1.5 | 19 | 19 | −1.4 | 20 | −4.4 | 21 | − | ||
| Change T4–T0 | 21 | − | 15 | 0.7 | 16 | −1.0 | 21 | −6.0 | 20 | −2.3 | |
| Change over time | 19 | P=0.22 | 17 | P=0.60 | 15 | P=0.74 | 19 | P=0.25 | 18 | P=0.15 | |
T0=at enrolment, T2=6 months following enrolment, T4=12 months following enrolment.
/indicates no data.
Scores range from 0 to 100; higher scores represent better quality of life in the domain.
Bold value means the difference in mean scores between two time points reaches the suggested MID
*Difference in mean scores between two time points reaches the suggested MID.
MID, minimally important difference.
Programme enablers
|
| |
| Addressing service gaps and extending service provision | I think you know that’s largely why this is in place because a lot of the men are in rural areas. So I think in that setting it’s very helpful. Pretty rare to get a psychiatrist or psychologist service on the phone. So in that sense like it’s sort of highly unique in Australia. (TNSP8) |
| Providing specialised services | In the public hospital I don’t think we’ve ever had anything for the patients like it before, so we’ve never been able to follow up with their incontinence or unless they’ve come back through clinic. But there’s never been anything like that or exercise they haven’t had these program available to them before, so I think it’s just better options for people, better opportunities. (Clinician4) |
| Supporting carers | We pick up that there might be issues with the partner’s distress and grief. But often feel our hands are tied as to what you can actually do for the partners. So I thought that was excellent support for carers and partners that I felt that perhaps I couldn't offer as well. (Clinician6) |
| Intervention related factors | |
| Needs-based approach | I think that TrueNTH is able to tailor to that, we’re able to give very personalised, individualised care. (TNSP1) |
| Telehealth based approach | When I first started with TrueNTH I was a little bit sceptical about whether I could develop the same rapport and provide the same support over, doing it as a telehealth service. But after working in the clinic, I was there for eight years, so doing it in a physical sense and I'm now doing it as a telehealth sense. There’s really no difference, I feel that I'm actually supporting these guys as well as I was working face to face. (TNSP3) |
| Care coordination | There’s the importance of having a skilled and knowledgeable coordinator who knows how to engage with both GPs and specialists is pretty key to this type of programme. I think that it needs to have to be able to build that trust with the specialist that the person is not lost in any particular when they’re getting some kind of shared care with the GP. (M1) |
| Healthcare provider factors | |
| Specialist expertise of TrueNTH team | Skilled clinicians is what the program sits on, whether it’s the exercise physiology or xx being dietician or the care coordinators, the commonality is our high levels of communication skills. (TNSP4) |
M, Movember representative; TNSP, TrueNTH service provider.
Programme barriers
|
| |
| Limitations of telehealth-based approach | The most difficult one is penile rehabilitation and the sexual rehabilitation and that’s really hard to do by distance. (Clinician1) |
| Insufficient resources and high caseload | Definitely needing to ensure dedicated, not just diary space or … but also physical space. I’ve always never been a fan of sort of open plan offices. That’s an impediment I think to sort of free-flowing interactions with patients…. So personal preference would be a room with dedicated access on that afternoon with a camera. That would be good I think that would hopefully diminish the intrusion of other demands, that requires widespread team sort of structure. (TNSP8) |
| Insufficient integration with existing services | It felt that we had to continually remind them. So even though this is a big teaching hospital with you know very good history of …. And possibly because of that everybody’s time and focus is so you know you have to keep reminding them that you’re there, that you’re present. And keep reminding them of the program. (Clinician6) |
| Healthcare provider factors | |
| Quality of team communication | I’d like it if there was better communication or integration between the clinicians, which cdmnet is not doing. Because it feels like to me once the care coordinator refers to us then it’s, like I said before there’s no feedback or overview. It feels like I can’t, when I feedback, I don’t know if it’s been accepted, I mean read, unless I prompt them…. You’re supposed to go back to the GP, people are trained to go back to their GP who coordinates everything. And if that’s the care coordinator then fine, but somehow the care coordinator still has to extract themselves out of the systems once it’s done so they still have to go back to the GP or the Specialist, and that bit I felt, that’s never been clear to me that that is being done nicely. (TNSP7) |
| Lower priority to supportive care issues | We are very, very busy clinics and sometimes you just don't have time with every prostate cancer patient …. To actually sit down with the guys individually and have a good chat about the project was probably a challenge for us…. But as I say just because of the sheer numbers we see and also we have kind of quite a lot of registrars and junior staff who are changing over quite frequently, who probably weren’t aware of all… all the staff of our unit weren’t aware of the program. So really I was the main one pushing for it and quite a lot of the other staff they just needed constant reminders and things. (Clinician3) |
| Patient related factors | |
| Perceptions of relevance of the service | You get things like people don't have the time, a lot of, especially with this demographic, they don't see the need for exercise. This is probably the main one is that feel, they basically don't see the need. One is that they don't care for exercise and they don't see a reason to do it, I guess the benefits of exercise is still a fairly new theory I guess, a new kind of treatment if you like. So a lot of the demographic that we look after just don't see the benefit for it and don't see why there’s a need. (TNSP5) |
| Reluctance to discuss needs | I don't want to be a grizzler.… He (TrueNTH care coordinator) rings up and I’ll tell him okay I’ll probably say yeah all good I'm doing alright. So I'm just not quite sure how much TrueNTH is aware of the bladder infections and the bowel complications and all that sort of stuff. I don't think that I’ve communicated that. (Patient34) |
| Reluctance/lack of confidence with technology | It’s not something I’ve used, not a lot of … I think there’s only been one of my guys that has wanted to use the video, they’re all quite happy with the phone calls. (TNSP3) |
M, movember representative; TNSP, TrueNTH service provider.